London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A dose ranging study in rabbits was performed to evaluate the effect of Chem-9 on corneal permeability and to assess the local irritation. Chem-9 was found to be effective in reducing corneal permeability and it shown no sign of local irritation. Potency of Chem-9 in reducing corneal permeability was comparable to cyclosporine (Restasis®; Allergan).
· Rabbit Ocular tolerance tests using Chem-9 showed no adverse signs such as inflammation, chemosis or hyperemia and no signs of local irritation.
If results good fro here - its sure winner ealry days - but next update and ist nulti-bagger from here.
ALso there have been 3 major/ senior appointments in August as nda/fda fast approaches. we shall see. for now people buying and holding, very good to see.
Ignore - the are children in play ground. OKYO unwards and upwards - nda and other results out soon. Saw soem large buys again today - they probaly bashing to buy. which is good. lol.
I see he's arrived here how many thousands has he invested now I'm talking pence not pounds as he tries to make out he's bought this & that but the amounts he says just never show he must buy by stealth anyways that's me avoiding this bb for a while won't be long before he's pi**sed everyone off
Well said Reprobus. I'm invested in OKYO, longer than you, we don't need your ramping. The BB is for discussing the pros and the cons, not ramping.
Mag,
I always do my research. My problem is you influencing inexperienced investors into buying on spikes! Icon does have potential yes, but it also has lots of risk but you never seem to mention that bit.
As I said on an earlier post, keep your poor advice to yourself!
reprobus ... always do your own dd. The fact i am buying ICON, yu dn't have to? and you don;t have to buy here either.
See. You don't now what you doing here.
All - Wise/good men talk about ideas/ insights, average ones talk about events, and sad/ novices kids talk about other people! you probably have seen some sad cases/kids here and other boards too. The share nothing of value about any stock. leave them to it - have filtered them all - they can talk to the hand.
are you stupid. OKYO still buying to 100k in OKYO, and 4 other stocks.
Reprobus, he sold icon this morning and he came straight here. He has no shame, he must be cutting and pasting his posts from icon here. They are exactly the same.
magmanus, this is a good share, it doesn't need you to ramp and put investors off.
He was telling people on the Icon board (mid September) to “buy and hold”, even while it was falling from 0.031p down time 0.011 over the space of a week. It hasn’t even come close to recovering since. His name has been mentioned a few times for being responsible for influencing people into buying on spikes.
If you’re reading this Magnus, just do us all a favour and stop giving out advice and spamming boards with your repetitive material.
bs and wasting yoru time - buy some here and icon, so you are not poorinvestor anymore. do some research
"MMs trying to fish - buy and hold." He must of used that 1000 times. I'm sure mms have a new technique by now.
Reprobus, exactly same ramps. He can't even find new ones, he uses the same ones again and again.
At Least come out with some new ramps, they are exactly same as ICON ramps.
How come you are doing exactly the same ramps here?
I don't get it. I'm invested here go away. I don't normally like to participate on this bb, but visit it regular, people on here don't need your Ramping.
I just don't get it. When I was invested in ICON, all I would read your ramps now I have to read them here.
maganus, r u still invested in icon?
Getting deja vu from reading these posts. Same ramping techniques which you used on Icon
Now i have done no research in this company and i am not here to bash it.
I'd just like to make everybody on this board aware that Mag is a certified ramper.
He'll pump this stock up, get out for a small profit and leave everybody else holding the baby!
Watch him!
So this is where Magnus the bullshi7 ramper has got to.. slithered off to another board like the snake he is
Ramp master 5000 get back over to icon, we need a laugh
well no-one else is....:) which is always good. have a finger in a few pies me. this is looks good to go, the heard will arrive to make £££
magmanus_49 -- looks like you're heavily invested here :)
Has played mjaor part at Tils and has expreince of NDA / FDA approvals.......Huge boost for OKYO with these big guys.
Dr Shailubhai is retiring from his role as a director of the Company and offers himself for reappointment.Kunwar Shailubhai, Ph.D., M.B.A. serves as chief executive officer, chief scientific officer and executive director of Tiziana Life Sciences plc. Dr. Shailubhai brings more than 25 years of experience within the life science industry, combined with a distinguished track record of success in translating drugs from concept through commercialisation to market. He also currently serves as chief executive officer of Rasna Therapeutics, Inc., a developer of therapeutics to address the high unmet need that exists for acute myeloid leukaemia and other forms of leukaemia.Dr. Shailubhai has been serving as a member of board of Tiziana Life Sciences plc since 2015. He actively played key roles in development of growth strategies through several key licensings of technologies and drug candidates. Dr. Shailubhai steered Tiziana Life Sciences plc through prioritisation of projects to focus on novel drug candidates for treatment of autoimmune and inflammatory diseases and cancer.As co-founder, executive vice-president and chief scientific officer of Synergy Pharmaceuticals, Inc. he led the non-clinical, chemistry, manufacture, controls and clinical development of TrulanceTM from inception to approval by the FDA, having co-invented and pioneered Synergy’s platform technology for functional gastrointestinal disorders, inflammatory bowel disease, gastrointestinal cancer and other human diseases. Dr. Shailubhai, as the chief architect of the intellectual property estate, directed all aspects of intellectual property management, including timely submission of patent applications, directing office actions and coordinating with intellectual property attorneys. Earlier, from 2003 until 2008, Dr. Shailubhai served as senior vice president, Drug Discovery and from 2001 to 2003, he held the position of vice president, Drug Discovery at Synergy, where he pioneered therapeutic applications of Guanylate Cyclease-C agonists in a variety of human diseases such as Asthma, Chronic Obstructive Pulmonary Disease and cholesterol lowering. Prior to Synergy, he was with Monsanto Company, serving as group leader, Cancer Prevention and previously served as a senior staff fellow at the National Institutes of Health, and as an assistant professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology from the University of Baroda, India, and his M.B.A. from the University of Missouri, St. Louis. He has more than 20 issued patents and over 50 peer-reviewed publications.
all stops taken by mms....looking good, and will press on, with your or without you. :)
OKYO board/ team currently exploring the use of OKYO-101 analogs for other inflammatory diseases such as Uveitis and Allergic Conjunctivitis..... £multi-billion mkts/ on update expect major re-rate from currently over sold pos. again decent buying today